Trials / Unknown
UnknownNCT03086785
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Hebei Medical University Fourth Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib single or combined capecitabine for treatment of patients with metastatic her-2 negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w |
Timeline
- Start date
- 2016-11-24
- Primary completion
- 2018-11-01
- Completion
- 2019-05-01
- First posted
- 2017-03-22
- Last updated
- 2018-01-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03086785. Inclusion in this directory is not an endorsement.